Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Germain

Showing results (301-310 of 332) with videos related to

Pageof 34
Sort By:
Virchows Archiv : an International Journal of Pathology|May 3, 2012
Ultrastructural scoring of skin biopsies for diagnosis of vascular Ehlers-Danlos syndromeKim-Thanh Ong, Henri Plauchu, Simone Peyrol, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 24, 2014
Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometryChristiane Auray-Blais, Catherine-Marie Blais, Uma Ramaswami, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Lancet (London, England)|September 10, 2010
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trialKim-Thanh Ong, Jérôme Perdu, Julie De Backer, et al.
European Journal of Pain (London, England)|August 5, 2024
Prevalence of Fabry disease in patients with chronic pain: Lessons from the DOUFAB and DOUFABIS studiesChloé Angelini, Claire Bar, Marie Pierre Baudier, et al.
Heart Failure Clinics|November 15, 2021
Diagnosis and Management of Cardiovascular Involvement in Fabry DiseaseMarta Rubino, Emanuele Monda, Michele Lioncino, et al.
Plos One|March 9, 2013
Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patientsBrandy Young-Gqamana, Nastry Brignol, Hui-Hwa Chang, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Pageof 34

Showing results (301-310 of 332) with videos related to

Sort By:
Pageof 34
Virchows Archiv : an International Journal of Pathology|May 3, 2012
Ultrastructural scoring of skin biopsies for diagnosis of vascular Ehlers-Danlos syndromeKim-Thanh Ong, Henri Plauchu, Simone Peyrol, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 24, 2014
Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometryChristiane Auray-Blais, Catherine-Marie Blais, Uma Ramaswami, et al.
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
ESC Heart Failure|February 27, 2020
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysisChristoph Wanner, Ulla Feldt-Rasmussen, Ana Jovanovic, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Lancet (London, England)|September 10, 2010
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trialKim-Thanh Ong, Jérôme Perdu, Julie De Backer, et al.
European Journal of Pain (London, England)|August 5, 2024
Prevalence of Fabry disease in patients with chronic pain: Lessons from the DOUFAB and DOUFABIS studiesChloé Angelini, Claire Bar, Marie Pierre Baudier, et al.
Heart Failure Clinics|November 15, 2021
Diagnosis and Management of Cardiovascular Involvement in Fabry DiseaseMarta Rubino, Emanuele Monda, Michele Lioncino, et al.
Plos One|March 9, 2013
Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patientsBrandy Young-Gqamana, Nastry Brignol, Hui-Hwa Chang, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Pageof 34